Immuneering Overview
- Founded
- 2008
- Status
- Acquired/Merged
- Employees
- 60
- Latest Deal Type
- Series B
- Latest Deal Amount
- $62M
- Investors
- 8
Immuneering General Information
Description
Developer of a disease canceling technology designed to forge a new approach to drug discovery, develop transformative medicines, and help others make the most of their data. The company's technology is focused on treating aspects of the disease that have eluded conventional approaches, including cancer cachexia and metastasis, enabling clients in the healthcare sectors to manufacture drugs to counteract several critical diseases.
Contact Information
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
- 245 Main Street
- 2nd Floor
- Cambridge, MA 02142
- United States
+1 (617) 000-0000
Immuneering Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 05-Jan-2021 | $62M | 0000 | Completed | Pre-Clinical Trials | |
| 2. Later Stage VC (Series A) | 16-Dec-2019 | 0000 | 0000 | 0000 | Completed | Pre-Clinical Trials |
| 1. Merger/Acquisition | 30-Sep-2015 | $60M | 00000 | Completed | Pre-Clinical Trials |
Immuneering Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Immuneering Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a disease canceling technology designed to forge a new approach to drug discovery, develop transformative m
Drug Discovery
Cambridge, MA
60
As of 2021
0000
00000000000
0000
000000 0
ip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum do
0000 000000000
Brisbane, CA
00
As of 0000
000.00
0000
0000-00-00
00000000000
000.00
00000000
a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt molli
0000 000000000
Houston, TX
00
As of 0000
00.000
0000000000 0
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialImmuneering Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Second Genome | Venture Capital-Backed | Brisbane, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000000 | Venture Capital-Backed | Houston, TX | 00 | 00.000 | 0000000000 0 | 00.000 |
| 0000000000 | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 00000000 | 00000 |
| 000000000 | Venture Capital-Backed | Ann Arbor, MI | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000000 | Formerly VC-backed | San Diego, CA | 0000 | 00000 | 000000&0 |
Immuneering Executive Team (6)
Immuneering Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bob Carpenter | Immuneering | Co-Founder & Board Member | 000 0000 |
| Joseph Kekst | Self | Board Member | 000 0000 |
| Peter Feinberg | Self | Board Observer | 000 0000 |
Immuneering Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial